Literature DB >> 8204272

Pituitary-gonadal dysfunction in male patients with lung cancer. Association with serum inhibin levels.

U Aasebø1, R M Bremnes, F H de Jong, A Aakvaag, L Slørdal.   

Abstract

Male lung cancer patients with poor performance status have an endocrinological dysfunction shown by decreased serum levels of total and free testosterone (AFTC). The intention was to investigate whether or not inhibin plays a role in gonadal dysfunction observed in male patients with malignant pulmonary disease. Twenty-seven patients with locally advanced non-small cell lung cancer were included. Sixteen patients were within ECOG index 1-2 (group A) and 11 patients within ECOG index 3-4 (group B). Gonadal function was monitored by serum LH, FSH, testosterone, SHBG and inhibin levels. Patients with poor performance status displayed significantly lower inhibin (1.6 +/- 0.8 U/I) and AFTC (0.23 +/- 0.07 nmol/l) levels when compared to patients within ECOG index 1-2 (inhibin 2.4 +/- 1.1 U/I; AFTC 0.66 +/- 0.36 nmol/l). Serum inhibin tended to correlate inversely to FSH with a 4.4-fold higher FSH/inhibin ratio in group B compared to A.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8204272     DOI: 10.3109/02841869409098401

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  2 in total

Review 1.  Nutritional status and muscle dysfunction in chronic respiratory diseases: stable phase versus acute exacerbations.

Authors:  Joaquim Gea; Antoni Sancho-Muñoz; Roberto Chalela
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

2.  Pituitary sex hormones enhance the pro‑metastatic potential of human lung cancer cells by downregulating the intracellular expression of heme oxygenase‑1.

Authors:  Ahmed Abdelbaset-Ismail; Daniel Pedziwiatr; Gabriela Schneider; Jacek Niklinski; Radoslaw Charkiewicz; Marcin Moniuszko; Magda Kucia; Mariusz Z Ratajczak
Journal:  Int J Oncol       Date:  2016-12-02       Impact factor: 5.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.